Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

被引：0

作者：

Rupert Bartsch

Simon Peter Gampenrieder

Gabriel Rinnerthaler

Edgar Petru

Daniel Egle

Andreas Petzer

Marija Balic

Ursula Pluschnig

Thamer Sliwa

Christian Singer

机构：

[1] Medical University of Vienna,Department of Medicine I, Division of Oncology

[2] Paracelsus Medical University Salzburg,Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center

[3] Medical University of Graz,University Hospital for Gynecology and Obstetrics, Clinical Department of Gynecology

[4] Medical University of Innsbruck,Department of Gynecology, Breast Cancer Center Tirol

[5] Ordensklinikum Linz GmbH,Barmherzige Schwestern, Elisabethinen, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology

[6] Medical University of Graz,Department of Internal Medicine, Division of Clinical Oncology

[7] Klagenfurt Hospital,Department of Internal Medicine and Hematology and Internal Oncology

[8] Hanusch Hospital,3rd Medical Department, Hematology and Oncology

[9] Medical University of Vienna,Department of Gynecology, Breast Cancer Center Vienna

来源：

Wiener klinische Wochenschrift | 2022年 / 134卷

关键词：

HER2; Trastuzumab; Pertuzumab; Antibody-conjugate; Tyrosin-kinase inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.

引用

页码：63 / 72

页数：9

共 50 条

[41] A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
Costa, Ricardo
Zaman, Saif
Sharpe, Susan
Helenowski, Irene
Shaw, Colleen
Han, Hyo
Soliman, Hatem
Czerniecki, Brian
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 309 - 316
[42] Trastuzumab for HER2+ breast cancer: more cardiac toxicities
Reactions Weekly, 2014, 1514 (1) : 5 - 5
[43] Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?
Lu, Christine Y.
Srasuebkul, Preeyaporn
Drew, Anna K.
Chen, Katie
Ward, Robyn L.
Pearson, Sallie-Anne
BREAST, 2013, 22 (04): : 482 - 487
[44] Predicting treatment outcome using kinome activity profiling in HER2+ breast cancer biopsies
Debets, Donna O.
de Graaf, Erik L.
Liefaard, Marte C.
Sonke, Gabe S.
Lips, Esther H.
Ressa, Anna
Altelaar, Maarten
ISCIENCE, 2024, 27 (06)
[45] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
Untch, Michael
Martin, Miguel
de Laurentiis, Michelino
Gligorov, Joseph
ONCOLOGY AND THERAPY, 2021, 9 (02) : 297 - 309
[46] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
Michael Untch
Miguel Martin
Michelino De Laurentiis
Joseph Gligorov
Oncology and Therapy, 2021, 9 : 297 - 309
[47] Treatment of HER2-Positive Metastatic Breast Cancer REPLY
Swain, Sandra M.
Clark, Emma
Baselga, Jose
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1965
[48] Updates in Treatment of HER2-positive Metastatic Breast Cancer
Avelino, Alzira R. M.
Pulipati, Soumya
Jamouss, Kevin
Bhardwaj, Prarthna V.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2024, 25 (12) : 1471 - 1481
[49] The changing treatment of metastatic her2-positive breast cancer
Mitsogianni, Maria
Trontzas, Ioannis P.
Gomatou, Georgia
Ioannou, Stephanie
Syrigos, Nikolaos K.
Kotteas, Elias A.
ONCOLOGY LETTERS, 2021, 21 (04)
[50] Optimizing treatment of HER2-positive metastatic breast cancer
Jones, AL
Leyland-Jones, B
SEMINARS IN ONCOLOGY, 2004, 31 (05) : 29 - 34

← 1 2 3 4 5 →